

CURRICULUM VITAE

Revised: May, 2017



Kyu-pyo Kim, M.D.

Associate Professor
Department of Oncology
Asan Medical Center
University of Ulsan College of Medicine
Seoul, Korea

Address (Work)

Department of Oncology
Asan Medical Center
88, Olympic-ro 43-gil, Songpa-gu
Seoul 05505 Korea
Tel: 82-2-3010-5913, 3010-3210
Fax: 82-2-3010-6961
e-mail: kkp1122@amc.seoul.kr

Education

| | |
|-------------------|---|
| 1993. 3 – 1995. 2 | Pre-Medicine College of Natural Sciences Ulsan University Ulsan, Korea |
| 1995. 3 – 1999. 2 | M.D. College of Medicine Ulsan University Seoul, Korea |

2002. 3 – 2004. 2 Master of Science
 College of Medicine
 Ulsan University
 Seoul, Korea
2007. 3 – 2010.2 Ph.D.
 Department of Clinical Pharmacology
 College of Medicine
 Seoul National University
 Seoul, Korea

Graduate Training

1999. 3 – 2000. 2 Internship
 Asan Medical Center
 Seoul, Korea
2000. 3 – 2004. 2 Residency, Internal Medicine
 Asan Medical Center
 Seoul, Korea
2007. 5 – 2009. 2 Fellowship
 Department of Clinical Pharmacology
 Seoul National University Hospital
 Seoul, Korea
2009. 3 – 2011.2 Fellowship, Oncology
 Department of Internal Medicine
 Asan Medical Center
 Seoul, Korea
2011. 3 – 2016.2 Assistant Professor, Oncology
 Department of Internal Medicine
 Asan Medical Center
 Seoul, Korea
2016. 3 – Associate Professor, Oncology
 Department of Internal Medicine
 Asan Medical Center
 Seoul, Korea

Professional Experience

- | | |
|--------------------|--|
| 2004. 4 – 2005. 3 | Medical Director Central Police Academy Chungju-City Chungbuk, Korea |
| 2005. 4 – 2007. 4 | Researcher Korea Health Industry Development Institute Ministry of Health, Welfare, and Family Affairs Seoul, Korea |
| 2014. 7 – 2016. 12 | Visiting Scholar University of Pittsburgh Cancer Pharmacokinetics and Pharmacodynamics Core Cancer Therapeutics Program |

Certification

- 2004 Diploma, Korean Board of Internal Medicine (#8696)

License

- 1999 Korean Medical License (#68433)

Affiliation

- Member, Korean Medical Association
- Member, Korean Association of Internal Medicine
- Member, Korean Cancer Association
- Member, Korean Association of Clinical Oncology
- Member, Korean Cancer Study Group
- Member, Korean Society for Clinical Pharmacology and Therapeutics
- Associate Member, American Society of Clinical Oncology

▪ **GCP Training & GCP study experience**

1. Clinical Research Methodology Workshop, Korean Cancer Study Group, June 27 2009
2. 2009 ASAN Medical Center GCP workshop, ASAN Medical Center, November 18 2009
3. 2010 ASAN Medical Center GCP Training September 2, 2010
4. 2011 ASAN Medical Center IRB Seminar : GCP Training for Investigators, ASAN Medical Center, March 18 2011

5. The Collaborative Institutional Training Initiative(CITI), Asan Medical Center, Dec 21 2012
6. 2013 Asan Medical Center IRB workshop, Asan Medical Center, Jul 05 2013
7. 임상연구개론: KGCP포함 07JUL2015
8. MFDS-Asan Joint Symposium on Rare Diseases 시험자 심화 교육(3H), 14JUL2016
9. GCP and 시험책임자 및 시험자 심화교육(3H), 08NOV2016
10. GCP and Education of persons conducting clinical trials, etc (4H), 19MAY.2017

Brief Summary of Relevant Clinical Research Experience:

1. 2015-Present, Sub-I, Phase II, Global SIT, Pembrolizumab, mCRC, 3rd or later line
2. 2015-Present, Sub-I, Phase III, Global SIT, Pembrolizumab vs SOC, mCRC, 1st line
3. 2013-Present, Sub-I, Phase III, Muticenter IIT, XELIRI±Bevacizumab vs FOLFIRI±Bevacizumab, mCRC, 2nd line

Publications in International Journals:

1. EUS in the evaluation of pancreatic cystic lesions. Song MH, Lee SK, Kim MH, Lee HJ, Kim KP, Kim HJ, Lee SS, Seo DW, Min YI. Gastrointest Endosc. 2003 Jun;57(7):891-6.
2. Ectopic opening of the common bile duct in the duodenal bulb: clinical implications. Lee SS, Kim MH, Lee SK, Kim KP, Kim HJ, Bae JS, Kim HJ, Seo DW, Ha HK, Kim JS, Kim CD, Chung JP, Min YI. Gastrointest Endosc. 2003 May;57(6):679-82.
3. Clinicopathologic review of 58 patients with biliary papillomatosis. Lee SS, Kim MH, Lee SK, Jang SJ, Song MH, Kim KP, Kim HJ, Seo DW, Song DE, Yu E, Lee SG, Min YI. Cancer. 2004 Feb;15;100(4):783-93.
4. Autoimmune pancreatitis: it may be a worldwide entity. Kim KP, Kim MH, Lee SS, Seo DW, Lee SK. Gastroenterology. 2004 Apr;126(4):1214.
5. Autoimmune chronic pancreatitis. Kim KP, Kim MH, Song MH, Lee SS, Seo DW, Lee SK. Am J Gastroenterol. 2004 Aug;99(8):1605-16
6. Accuracy of magnetic resonance cholangiopancreatography for locating hepatolithiasis and detecting accompanying biliary strictures. Park DH, Kim MH, Lee SS, Lee SK, Kim KP, Han JM, Kim SY, Song MH, Seo DW, Kim AY, Kim TK, Min YI. Endoscopy. 2004 Nov;36(11):987-92.
7. Regression of pancreatic fibrosis after steroid therapy in patients with autoimmune chronic pancreatitis. Song MH, Kim MH, Lee SK, Seo DW, Lee SS, Han J, Kim KP, Min YI, Song DE, Yu E, Jang SJ. Pancreas. 2005 Jan;30(1):83-6.
8. Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy

- male volunteers in Korea. Kim BH, Yi S, Kim J, Lim KS, Kim KP, Lee B, Shin SG, Jang IJ, Yu KS. Clin Ther. 2009 Jun;31(6):1234-43.
9. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. Kim TE, Kim BH, Kim JR, Lim KS, Hong JH, Kim KP, Kim HS, Shin SG, Jang IJ, Yu KS. Br J Clin Pharmacol. 2009 Jul;68(1):43-6.
 10. Potential interactions between cilostazol and probucol: a two-part, single-dose, open-label study in healthy Korean male volunteers. Kim KP, Kim BH, Lim KS, Kim TE, Shin SG, Jang IJ, Yu KS. Clin Ther. 2009 Oct;31(10):2098-106.
 11. Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers. Kim TE, Kim BH, Kim J, Kim KP, Yi S, Shin HS, Lee YO, Lee KH, Shin SG, Jang IJ, Yu KS. Clin Ther. 2009 Oct;31(10):2249-57.
 12. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers. Kim BH, Shin KH, Kim J, Lim KS, Kim KP, Kim JR, Cho JY, Shin SG, Jang IJ, Yu KS. Clin Ther. 2009 Nov;31(11):2755-64.
 13. Pharmacodynamic (Hemodynamic) and pharmacokinetic comparisons of S-amlodipine gentisate and racemate amlodipine besylate in healthy Korean male volunteers: two double-blind, randomized, two-period, two-treatment, two-sequence, double-dummy, single-dose crossover studies. Kim BH, Kim JR, Kim MG, Kim KP, Lee BY, Jang IJ, Shin SG, Yu KS. Clin Ther. 2010 Jan;32(1):193-205.
 14. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. Kim KP, Jang G, Hong YS, Lim HS, Bae KS, Kim HS, Lee SS, Shin JG, Lee JL, Ryu MH, Chang HM, Kang YK, Kim TW. Br J Cancer. 2011 Feb;104(4):605-12.
 15. A phase I study of S-1 treatment with a 3 week schedule in advanced biliary cancer patients with or without hepatic dysfunction. Yoon DH, Lee HJ, Hong YS, Kim KP, Lee SS, Lee JL, Chang HM, Ryu MH, Kang YK, Lee JS, Kim TW. Invest New Drugs. 2011 Apr;29(2):332-9..
 16. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. Kim KP, Ryu MH, Yoo C, Ryoo BY, Choi DR, Chang HM, Lee JL, Beck MY, Kim TW, Kang YK. Cancer Chemother Pharmacol. 2011 Aug; 68(2):285-91.
 17. Pharmacokinetics of a fixed-dose glimepiride/sustained-release metformin combination. Kim KP, Lim KS, Kim BH, Shin HS, Cho JY, Shin SG, Jang IJ, Yu KS. Int J Clin Pharm Th. 2012 Feb;50(2):142-9

18. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy. Kim KP, Ahn JH, Kim SB, Jung KH, Yoon DH, Lee JS, Ahn SH. *Cancer chemother Pharmacol*. 2012 May;69(5):1221-7.
19. The Survivin Suppressant YM155 Potentiates Chemosensitivity to Gemcitabine in the Human Pancreatic Cancer Cell Line MiaPaCa-2. Yoon DH, Shin JS, Jin DH, Hong SW, Jung KA, Kim SM, Hong YS, Kim KP, Lee JL, Suh CW, Lee JS, Kim TW. *Anticancer Res*. 2012 May;32(5):1681-88.
20. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1. Hong YS, Hong SW, Kim SM, Jin DH, Shin JS, Yoon DH, Kim KP, Lee JL, Heo DS, Lee JS, Kim TW. *Int J Oncol*. 2012 Jul;41(1):76-82.
21. RING finger protein 149 is an E3 ubiquitin ligase active on wild-type BRAF. Hong SW, Jin DH, Shin JS, Moon JH, Na YS, Jung KA, Kim SM, Kim JC, Kim KP, Hong YS, Lee JL, Choi EK, Lee JS, Kim TW. *J Biol Chem*. 2012 Jul;287(28):24017-25.
22. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Kang MJ, Hong YS, Kim KP, Kim SY, Baek JY, Ryu MH, Lee JL, Chang HM, Kim MJ, Chang HJ, Kang YK, Kim TW. *Invest New Drugs*. 2012 Aug;30(4):1607-13.
23. Genetic Polymorphisms of FcγRIIa-FcγRIIIa are not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer. Park SJ, Hong YS, Lee JL, Ryu MH, Chang HM, Kim KP, Ahn YC, NA YS, Jin DH, YU CS, Kim JC, Kang YK, Kim TW. *Oncology*. 2012;82(2):83–89.
24. A Phase II Study of Clinical Outcomes of 3-Week Cycle of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity. Choi YH, Kim TW, Kim KP, Lee SS, Hong YS, Ryu MH, Lee JL, Chang HM, Ryoo BY, Kim HS, Shin JG, Kang YK. *Oncology*. 2012;82(5):290-297.
25. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, Lee JS. *Lung Cancer*. 2012 Sep;77(3):556-60.
26. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomized, non-inferiority phase 3 trial. Hong YS, Park YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Jo SJ, Lee JW. *Lancet Oncol*. 2012 Nov;13(11):1125-32.
27. Phase II Study of Preoperative Chemoradiation with S-1 plus Oxaliplatin in Patients with Locally Advanced Rectal Cancer. Lee EM, Hong YS, Kim KP, Lee JL, Kim SY, Park YS, Choi

- DH, Kim JH, Lim SB, Yu CS, Kim JC, Lee JH, Kim AY, Kim TW. *Cancer Sci.* 2013 Jan;104(1):111-5.
28. A Phase I Study of DHP107, an Mucoadhesive Lipid Form of Oral Paclitaxel, Patients with Advanced Solid Tumors: Crossover comparisons with intravenous paclitaxel. Hong YS, Kim KP, Lim HS, Bae KS, Ryu MH, Lee JL, Chang HM, Kang YK, Kim H, Kim TW. *Invest New Drugs.* 2013 Jun;31(3):616-22.
29. Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy. Hong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, Park SH, Kim SY, Baek JY, Kim JH, Lee KW, Kim TY, Kim TW. *Invest New Drugs.* 2013 Feb;31(1):183-191.
30. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. Jo JC, Hong YS, Kim KP, Lee JL, Kim HJ, Lee MW, Lim SB, Yu CS, Kim JC, Kim JH, Kim TW. *Eur J Dermatol.* 2013 Feb;23(1):77-82.
31. Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer. Kim JC, HA YJ, Roh SA, Choi EY, Yoon YS, Kim KP, Hong YS, Kim TW, Cho DH, Kim SY, Kim YS. *Br J Cancer.* 2013 Mar;108(9):1862-9.
32. Second-line Cetuximab/Irinotecan Versus Oxaliplatin/ Fluoropyrimidines for Metastatic Colorectal Cancer with Wild-type KRAS. Hong YS, Kim HJ, Park SJ, Kim KP, Lee JL, Park JH, Kim JH, Lim SB, Yu CS, Kim JC, Baek JY, Kim SY, Kim TW. *Cancer Sci.* 2013 Apr;104(4):473-80.
33. A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. Kim KP, Kim HS, Sym SJ, Bae KS, Hong YS, Chang HM, Lee JL, Kang YK, Lee JS, Shin JG, Kim TW. *Cancer Chemother Pharmacol.* 2013 Jun;71(6):1609-1617.
34. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. Ji JH, Park SH, Lee J, Kim TW, Hong YS, Kim KP, Kim SY, Baek JY, Kang HJ, Shin SJ, Shim BY, Park YS. *Cancer Chemother Pharmacol* 2013 Jul;72(1):223-30
35. 3'-Deoxy-3'-18F-Fluorothymidine PET for the Early Prediction of Response to Leucovorin, 5-Fluorouracil, and Oxaliplatin Therapy in Patients with Metastatic Colorectal Cancer. Hong YS, Kim HO, Kim KP, Lee JL, Kim HJ, Lee SJ, Lee SJ, Oh SJ, Kim JS, Ryu JS, Moon DH, Kim TW. *J Nucl Med.* 2013 Aug;54(8):1209-16.
36. Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: A prospective, multicenter trial of the Korean cancer study group CO06-01. Hong YS, Jung KH, Kim HJ, Kim KP, Kim SY, Lee JL, Shim BY, Zang DY, Kim JH, Ahn JB, Park YS, Kim TW. *Am J Clin Oncol.* 2013

- Dec;36(6):565-71.
37. A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer: A Preprospective, Multicenter Trial of the Korean Cancer Study Group. Hong YS, Lee SS, Kim KP, Lee JL, Kang YK, Shin SJ, Ahn JB, Jung KH, Im SA, Kim TY, Kim JH, Park YS, Kim TW. *Am J Clin Oncol*. 2014 Feb;37(1):19-23.
 38. The role of 18F-fluorodeoxyglucose positron emission tomography at response assessment after autologous stem cell transplantation in T-cell non-Hodgkin's lymphoma patients. Sohn BS, Yoon DH, Kim KP, Kim S, Lee KM, Park JS, Lee DH, Ryu JS, Huh J, Hong IK, Suh C. *Ann Hematol*. 2013 Aug;54(8):1209-16.
 39. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells. Park SJ, Hong SW, Moon JH, Jin DH, Kim JS, Lee CK, Kim KP, Hong YS, Choi EK, Lee JS, Lee JL, Kim TW. *Am J Med Sci*. 2013 Dec;346(6):494-8.
 40. p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTEN. Hong SW, Moon JH, Kim JS, Shin JS, Jung KA, Lee WK, Jeong SY, Hwang JJ, Lee SJ, Suh YA, Kim I, Nam KY, Han S, Kim JE, Kim KP, Hong YS, Lee JL, Lee WJ, Choi EK, Lee JS, Jin DH, Kim TW. *Cell Death Differ*. 2014 Jan;21(1):146-60.
 41. NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants. Shin JS, Hong SW, Moon JH, Kim JS, Jung KA, Kim SM, Lee DH, Kim I, Yoon SJ, Lee CG, Choi EK, Lee JY, Kim KP, Hong YS, Lee JL, Kim B, Choi EK, Lee JS, Jin DH, Kim TW. *Invest New Drugs*. 2014 Jun;32(3):389-99.
 42. High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases. Shin JS, Hong SW, Moon JH, Kim JS, Jung KA, Kim SM, Lee DH, Kim I, Yoon SJ, Lee CG, Choi EK, Lee JY, Kim KP, Hong YS, Lee JL, Kim B, Choi EK, Lee JS, Jin DH, Kim TW. *Invest New Drugs*. 2014 Jun;32(3):389-99.
 43. A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Jo JC, Hong YS, Kim KP, Lee JL, Lee J, Park YS, Kim SY, Ryu JS, Lee JS, Kim TW. *Invest New Drugs*. 2014 Apr;32(2):369-76.
 44. NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype. Hong SW, Shin JS, Moon JH, Kim YS, Lee J, Choi EK, Ha SH, Lee DH, Chung HN, Kim JE, Kim KP, Hong YS, Lee JL, Lee WJ, Choi EK, Lee JS, Jin DH, Kim TW. *Apoptosis*. 2014 May;19(5):895-904.
 45. Primary mesenchymal tumors of the pancreas: single-center experience over 16 years. Kim JY, Song JS, Park H, Byun JH, Song KB, Kim KP, Kim SC, Hong SM. *Pancreas*. 2014 Aug;43(6):959-68.
 46. Single-nucleotide polymorphisms in the vascular endothelial growth factor pathway and

- outcomes of patients treated with first-line cytotoxic chemotherapy combined with bevacizumab for advanced colorectal cancer. Sohn BS, Park SJ, Kim JE, Kim KP, Hong YS, Suh C, Kim YS, Kim SY, Im SA, Kim SY, Kim JH, Ahn JB, Park YS, Kim TW. *Oncology*. 2014;87(5):280-92.
47. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW. *Lancet Oncol*. 2014 Oct;15(11):1245-53.
 48. Origin-dependent neural cell identities in differentiated human iPSCs in vitro and after transplantation into the mouse brain. Hargus G, Ehrlich M, Araúzo-Bravo MJ, Hemmer K, Hallmann AL, Reinhardt P, Kim KP, Adachi K, Santourlidis S, Ghanjati F, Fauser M, Ossig C, Storch A, Kim JB, Schwamborn JC, Sternecker J, Schöler HR, Kuhlmann T, Zaehres H. *Cell Rep*. 2014 Sep 25;8(6):1697-703.
 49. Survival effect of tumor size and extrapancreatic extension in surgically resected pancreatic cancer: proposal for improved T classification. Park H, An S, Eo SH, Song KB, Park JH, Kim KP, Lee SS, Cho H, Seo DW, Kim SC, Yu E, Hong SM. *Hum Pathol*. 2014 Nov;45(11):2341-6.
 50. Postoperative radiotherapy for gallbladder cancer. Jeong Y, Park JH, Lee YJ, Park KM, Hwang S, Chang HM, Kim KP, Yoon SM, Jung NH, Kim JH. *Anticancer Res*. 2014 Oct;34(10):5621-9.
 51. TFAP2E methylation status and prognosis of patients with radically resected colorectal cancer. Park SJ, Kim SM, Hong YS, Lee JL, Kim JE, Kim KP, Hong SM, Jin DH, Kim CW, Yoon YS, Park IJ, Lim SB, Yu CS, Kim JC, Kim TW. *Oncology*. 2015;88(2):122-32.
 52. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation. Koo DH, Kim KP, Choi CM, Lee DH, Lee JC, Lee JS, Jang SJ, Kim SW. *Cancer Chemother Pharmacol*. 2015 Jan;75(1):197-206.
 53. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. Kim JE, Hong YS, Lee JL, Kim KP, Park SJ, Sym SJ, Shin DB, Lee J, Park YS, Ahn JS, Kim TW. *Support Care Cancer*. 2015 Jun;23(6):1769-77.
 54. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors. Kim JY, Kim MS, Kim KS, Song KB, Lee SH, Hwang DW, Kim KP, Kim HJ, Yu E, Kim SC, Jang HJ, Hong SM. *Am J Surg Pathol*. 2015 May;39(5):592-601.
 55. Cellular inhibitor of apoptosis protein 1 (cIAP1) stability contributes to YM155 resistance in human gastric cancer cells. Jung SA, Park YM, Hong SW, Moon JH, Shin JS, Lee HR, Ha SH, Lee DH, Kim JH, Kim SM, Kim JE, Kim KP, Hong YS, Choi EK, Lee JS, Jin DH, Kim T.

- J Biol Chem. 2015 Apr 17;290(16):9974-85.
56. Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer. Kim ST, Kim TW, Kim KP, Kim TY, Han SW, Lee JY, Lim SH, Lee MY, Kim H, Park YS. Cancer Res Treat. 2015 Oct;47(4):790-5.
 57. Initial human experience of endoscopic ultrasound-guided photodynamic therapy with a novel photosensitizer and a flexible laser-light catheter. Choi JH, Oh D, Lee JH, Park JH, Kim KP, Lee SS, Lee YJ, Lim YS, Song TJ, Lee SS, Seo DW, Lee SK, Kim MH, Park do H. Endoscopy. 2015 Nov;47(11):1035-8.
 58. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies. Kim KP, Park SJ, Kim JE, Hong YS, Lee JL, Bae KS, Cha H, Kwon SK, Ro S, Cho J, Kim TW. Invest New Drugs. 2015 Oct;33(5):1048-57.
 59. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy. Kim JE, Hong YS, Kim HJ, Kim KP, Lee JL, Park SJ, Lim SB, Park IJ, Kim CW, Yoon YS, Yu CS, Kim JC, Hoon KJ, Kim TW. Ann Surg Oncol. 2015 Dec;22 Suppl 3:S630-7.
 60. A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer. Moon JH, Shin JS, Hong SW, Jung SA, Hwang IY, Kim JH, Choi EK, Ha SH, Kim JS, Kim KM, Hong DW, Kim D, Kim YS, Kim JE, Kim KP, Hong YS, Choi EK, Lee JS, Hattersley M, Jin DH, Kim TW. Oncotarget. 2015 Sep 29;6(29):26895-908.
 61. Targeting FGFR Pathway in Human Hepatocellular Carcinoma: Expressing pFGFR and pMET for Antitumor Activity. Jo JC, Choi EK, Shin JS, Moon JH, Hong SW, Lee HR, Kim SM, Jung SA, Lee DH, Jung SH, Lee SH, Kim JE, Kim KP, Hong YS, Suh YA, Jang SJ, Choi EK, Lee JS, Jin DH, Kim TW. Mol Cancer Ther. 2015 Nov;14(11):2613-22.
 62. SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin. Park SJ, Kim SM, Moon JH, Kim JH, Shin JS, Hong SW, Shin YJ, Lee DH, Lee EY, Hwang IY, Kim JE, Kim KP, Hong YS, Lee WK, Choi EK, Lee JS, Jin DH, Kim TW. Tumour Biol. 2016 Apr;37(4):4323-30.
 63. L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells. Jung SA, Lee DH, Moon JH, Hong SW, Shin JS, Hwang IY, Shin YJ, Kim JH, Gong EY, Kim SM, Lee EY, Lee S, Kim JE, Kim KP, Hong YS, Lee JS, Jin DH, Kim T, Lee WJ. Free Radic Biol Med. 2016 Jun;95:200-8.
 64. Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer. Kim D, Hong YS, Kim JE, Kim KP, Lee JL, Chun SM, Kim J, Jang SJ, Kim TW. Cancer Res Treat. 2017 Jan;49(1):37-43.
 65. Foxp3 is a key downstream regulator of p53-mediated cellular senescence. Kim JE, Shin

- JS, Moon JH, Hong SW, Jung DJ, Kim JH, Hwang IY, Shin YJ, Gong EY, Lee DH, Kim SM, Lee EY, Kim YS, Kim D, Hur D, Kim TW, Kim KP, Jin DH, Lee WJ. *Oncogene*. 2017 Jan 12;36(2):219-230.
66. Phase II Study of Preoperative Capecitabine and Oxaliplatin-based Intensified Chemoradiotherapy With or Without Induction Chemotherapy in Patients With Locally Advanced Rectal Cancer and Synchronous Liver-limited Resectable Metastases. Cho H, Kim JE, Kim KP, Yu CS, Kim JC, Kim JH, Lee MA, Jang HS, Oh ST, Kim SY, Oh JH, Kim DY, Hong YS, Kim TW. *Am J Clin Oncol*. 2016 Dec;39(6):623-629.
67. Paired Primary and Metastatic Tumor Analysis of Somatic Mutations in Synchronous and Metachronous Colorectal Cancer. Kim KP, Kim JE, Hong YS, Ahn SM, Chun SM, Hong SM, Jang SJ, Yu CS, Kim JC, Kim TW. *Cancer Res Treat*. 2017 Jan;49(1):161-167.
68. Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer. Jeong JH, Hong YS, Park Y, Kim J, Kim JE, Kim KP, Kim SY, Park JH, Kim JH, Park IJ, Lim SB, Yu CS, Kim JC, Kim TW. *Int J Radiat Oncol Biol Phys*. 2016 Oct 1;96(2):289-95.
69. Corrigendum to 'L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells': [Free Radic. Biol. Med. 95 (2016) 200-208]. Jung SA, Lee DH, Moon JH, Hong SW, Shin JS, Hwang IY, Shin YJ, Kim JH, Gong EY, Kim SM, Lee EY, Lee S, Kim JE, Kim KP, Hong YS, Lee JS, Jin DH, Kim T, Lee WJ. *Free Radic Biol Med*. 2016 Aug;97:620.
70. Polymeric nanoparticle-docetaxel for the treatment of advanced solid tumors: phase I clinical trial and preclinical data from an orthotopic pancreatic cancer model. Song SY, Kim KP, Jeong SY, Park J, Park J, Jung J, Chung HK, Lee SW, Seo MH, Lee JS, Jung KH, Choi EK. *Oncotarget*. 2016 Nov 22;7(47):77348-77357.
71. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer. Park K, Kim KP, Park S, Chang HM. *Asia Pac J Clin Oncol*. 2017 Feb;13(1):13-20.
72. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX). Kim JE, Hong YS, Kim HJ, Kim KP, Kim SY, Lim SB, Park IJ, Kim CW, Yoon YS, Yu CS, Kim JC, Kim JH, Kim TW. *Ann Surg Oncol*. 2016 Nov 16. [Epub ahead of print].
73. Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-containing Regimen. Yoo C, Kim BJ, Kim KP, Lee JL, Kim TW, Ryoo BY, Chang HM. *Cancer Res Treat*. 2016 Nov 9. [Epub ahead of print].
74. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Yoo C, Cho H, Song MJ, Hong SM, Kim KP, Chang HM, Chae H, Kim TW, Hong YS, Ryu MH, Kang YK, Kim SC, Ryoo BY. *Cancer Chemother Pharmacol*.

2017 Jan;79(1):139-146.

75. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Kim BJ, Yoo C, Kim KP, Hyung J, Park SJ, Ryoo BY, Chang HM. Br J Cancer. 2017 Feb 28;116(5):561-567.
76. Postoperative Radiotherapy for Pancreatic Cancer with Microscopically-positive Resection Margin. Park S, Kim SC, Hong SM, Lee YJ, Park KM, Hwang DW, Lee JH, Song KB, Ryoo BY, Jang HM, Kim KP, Yu C, Choi EK, DO Ahn S, Lee SW, Yoon SM, Park JH, Kim JH. Anticancer Res. 2017 Feb;37(2):755-764.
77. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. Kim JW, Lee KW, Kim KP, Lee JH, Hong YS, Kim JE, Kim SY, Park SR, Nam BH, Cho SH, Chung IJ, Park YS, Oh HS, Lee MA, Kang HJ, Park YI, Song EK, Han HS, Lee KT, Shin DB, Kang JH, Zang DY, Kim JH, Kim TW. Oncologist. 2017 Mar;22(3):293-303.
78. Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS. Kim KP, Parise RA, Holleran JL, Lewis LD, Appleman L, van Erp N, Morris MJ, Beumer JH. J Pharm Biomed Anal. 2017 Feb 13;138:197-205.
79. HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF. Jeong JH, Kim J, Hong YS, Kim D, Kim JE, Kim SY, Kim KP, Yoon YK, Kim D, Chun SM, Park Y, Jang SJ, Kim TW. Clin Colorectal Cancer. 2017 Jan 25. [Epub ahead of print].